ABOUT IQVIA RESEARCH & DEVELOPMENT SOLUTIONS

Through our CORE-powered approach to clinical development, IQVIA will help you rethink old challenges into new opportunities and surround your trial with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring differentiated therapies to patients sooner.

Throughout the COVD-19 pandemic, IQVIA has helped sponsors bring trials closer to the patients with our decentralized trial capabilities – from remote monitoring to telemedicine, direct-to-patient shipment of investigational medicines and the use of home health nurses in clinical research.

IQVIA Decentralized Trials brings studies directly to patients wherever they are — as 100% remote studies or as hybrids blending patient-centric approaches with traditional site-based elements. Our decentralized model offers the adaptability necessary to meet any sponsor’s requirements — small or large, local or global.

Learn how IQVIA Decentralized Trials can expand your geographic reach, providing access to diverse populations and difficult-to-recruit candidates, and solving some of the toughest clinical trials challenges.

THOUGHT LEADERSHIP

  • When we talk about decentralized clinical trials (DCTs), the conversation usually centers on the technology however DCTs require more than technology. There is an equally important human component driven by specialized study teams, including mobile research nurses and phlebotomists who engage patients where they live. This blog explores how mobile research teams have become the unsung heroes of the tech-enabled clinical trials movement.

  • Sponsors have discovered that it is not easy to assemble a perfectly diverse patient population that also meets all inclusion/exclusion criteria. Facing the simultaneous pressure to lower costs and accelerate timelines, diversity goals can often slide down the priority list. However, the growing adoption of decentralized clinical trials (DCTs) may now help make recruiting diverse, representative groups of participants more achievable – without adding significant time and cost to the trial.

  • Patient attrition has always been a challenge in clinical research, but the use of decentralized clinical trials (DCTs) may help sponsors overcome attrition problems. Learn what clinical trial models can bolster retention and greater engagement between patients, investigators and sponsors.   

  • The biopharmaceutical industry in China, like the rest of the world, was forced to swiftly adopt decentralized clinical trial (DCT) approaches to maintain progress during to the COVID-19 pandemic. And, like the rest of the world, its patients, investigators and sponsors were hopeful about the benefits of using these tools. Surveys show patients, sponsors and CROs in China see the benefits of virtual and hybrid trials. Concerns remain around regulatory gaps, digital data collection and study logistics.

  • The global pandemic has added complexity to the already nuanced clinical development landscape, making innovation within clinical research critical to advancing human health. There are many factors that play a role in how trial adjustments are implemented. This paper will discuss how clinical trial models are evolving as sponsors rethink the traditional research paradigm and adopt patient-centric clinical technologies and approaches, including telemedicine and remote clinical monitoring.

  • Long-term follow-up studies can be expensive and time-consuming for investigators, sponsors and patients. Read how virtual models can improve patient retention in long-term follow-up studies, cutting the time, cost and burden for patients and investigators.

  • COVID-19 accelerated interest in the use of virtual trials as a way to keep trials running through the pandemic. It was an unexpected shift, but it has helped many sponsors and sites see the value of virtual for clinical research and identify where and when virtual trial elements may bring permanent benefits to clinical research, even after the pandemic is over.

  • There is no question that decentralized clinical trials are transforming the clinical research environment. This patient-centric approach to research is making it possible for sponsors to engage with a more diverse patient population, accelerate recruiting, and lower the burden of trial participation. If research participants no longer attend site visits, they wonder, what is the point of the site in clinical trials? Investigators need not worry.

  • Digital therapeutics are showing the potential to be the next frontier for value-driven precision medicine promising to add value for patients, payers and pharma. Virtual trial models are designed with the same goal in mind; a formula that everyone in the industry can get behind.

CONTACT INFORMATION

IQVIA Research & Development Solutions

4820 Emperor Blvd.

Durham, NC 27703

UNITED STATES

Phone: (919) 998-2000

Contact: David Tripi

FEATURED ARTICLES

  • The Human Touch Of Decentralized Clinical Trials
    7/1/2021

    When we talk about decentralized clinical trials (DCTs), the conversation usually centers on the technology however DCTs require more than technology. There is an equally important human component driven by specialized study teams, including mobile research nurses and phlebotomists who engage patients where they live. This blog explores how mobile research teams have become the unsung heroes of the tech-enabled clinical trials movement.

  • Can Decentralized Clinical Trials Solve Attrition? Early Research Suggests ‘Yes.’
    3/12/2021

    Patient attrition has always been a challenge in clinical research, but the use of decentralized clinical trials (DCTs) may help sponsors overcome attrition problems. Learn what clinical trial models can bolster retention and greater engagement between patients, investigators and sponsors.   

  • Partnerships In The Pandemic: Deploying eConsent For Remote And Hybrid Studies
    3/3/2021

    This 20-minute webinar gives the latest information from hands-on experience with eConsent implementations for new and ongoing trials in the COVID-19 era. Learn about the benefits that can be gained from remote consent for patients and sites and the changing regulatory landscape that is enabling adoption in a growing number of countries and regions.

  • Will Virtual Trials Mean The End Of CROs?
    11/4/2019

    Virtual trials are growing in acceptance. The patient-centric aspect of these trials makes them easier to recruit and retain patients and accelerate timelines, while also providing patient data to researchers in real time. But will virtual trials also mean the end of CROs?

  • Virtual Absolution: How Trial Sites Adapted To COVID-19
    2/4/2021

    COVID-19 accelerated interest in the use of virtual trials as a way to keep trials running through the pandemic. It was an unexpected shift, but it has helped many sponsors and sites see the value of virtual for clinical research and identify where and when virtual trial elements may bring permanent benefits to clinical research, even after the pandemic is over.

  • Delivering Clinical Trial Continuity During COVID-19
    2/4/2021

    The global pandemic has added complexity to the already nuanced clinical development landscape, making innovation within clinical research critical to advancing human health. There are many factors that play a role in how trial adjustments are implemented. This paper will discuss how clinical trial models are evolving as sponsors rethink the traditional research paradigm and adopt patient-centric clinical technologies and approaches, including telemedicine and remote clinical monitoring.

  • Remote Consent: Adjusting To The New Normal In Clinical Trials
    6/3/2020

    The global pandemic has brought the need to enrol new patients quickly in COVID19-related trials and keep patient engagement high in ongoing trials, even as face-to-face interactions are limited. This presentation will review sponsor and site frequently asked questions about electronic and remote consent capabilities as they seek to consent patients in new and faster ways.